Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.48 |
| ▸ | TDO2 | P48775 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23199574 | 0.87 | AKR1C3 (0.51) | ERN1TDO2CYP3A4ALDH1A1CYP2A6 | |
| SCHEMBL2649875 | 0.81 | PARP1 (0.39) | PARP1ABL1AKR1C3AKR1C2GABRA1 | |
| SCHEMBL18519105 | 0.81 | MGLL (0.52) | AKR1C3AKR1C2BACE1 | |
| SCHEMBL2666033 | 0.80 | NUDT1 (0.41) | CYP1A2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL15624620 | 0.80 | TDO2 (0.56) | ERN1TDO2CYP3A4ALDH1A1CYP2A6 | |
| SCHEMBL2651849 | 0.79 | CYP11B2 (0.33) | CYP11B2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL28115752 | 0.78 | CYP2A6 (0.51) | ERN1TDO2CYP3A4ALDH1A1CYP2A6 | |
| SCHEMBL2665898 | 0.77 | CYP2A6 (0.51) | ERN1TDO2CYP3A4ALDH1A1CYP2A6 | |
| SCHEMBL2649040 | 0.77 | CYP11B2 (0.54) | ERN1TDO2CYP3A4ALDH1A1CYP2A6 | |
| SCHEMBL2649494 | 0.77 | AXL (0.56) | ERN1TDO2CYP3A4ALDH1A1CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7279580-B2 | Imidazo-pyridine derivatives as ligands for GABA receptors | MERCK SHARP & DOHME LIMITED (GB) | 2007-10-09 | — | — | US | disclosed |
| EP-1511747-B1 | IMIDAZO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2006-04-12 | — | — | EP | disclosed |
| US-20050165048-A1 | Imidazo-pyridine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. (GB) | 2005-07-28 | — | — | US | disclosed |
| EP-1381606-B1 | IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2005-07-20 | — | — | EP | disclosed |
| US-6900215-B2 | For therapy of disorders of central nervous system, including anxiety, convulsions and cognitive disorders | MERCK SHARP & DOHME LTD. (GB) | 2005-05-31 | — | — | US | disclosed |
| EP-1511747-A1 | IMIDAZO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2005-03-09 | — | — | EP | disclosed |
| EP-1381606-A1 | IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2004-01-21 | — | — | EP | disclosed |
| WO-2003099816-A1 | IMIDAZO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2003-12-04 | — | — | WO | disclosed |
| US-20020193385-A1 | Imidazo-pyrimidine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2002-12-19 | — | — | US | disclosed |
| WO-2002074773-A1 | IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2002-09-26 | — | — | WO | disclosed |
| WO-2002074772-A1 | IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193385-A1 | Imidazo-pyrimidine derivatives as ligands for gaba receptors | GABRA3, GABRA1, GABRA2 | ERN1 2655/4885TDO2 1037/4885CYP3A4 244/4885 |
| US-20050165048-A1 | Imidazo-pyridine derivatives as ligands for gaba receptors | GABRA3, GABRA2, GABRA5 | ERN1 3396/4885TDO2 1290/4885CYP3A4 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.